Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome

BACKGROUND: Individuals with Down syndrome are likely to develop clinical and neuropathological brain changes resembling Alzheimer’s disease dementia by the ages of 35–40 years. Intranasal insulin is a potential treatment for neurodegenerative disease that has been shown to reduce amyloid plaque bur...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Drugs R D
Huvudupphovsmän: Rosenbloom, Michael, Barclay, Terry, Johnsen, Justin, Erickson, Lauren, Svitak, Aleta, Pyle, Maria, Frey, William, Hanson, Leah R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2020
Ämnen:
Original Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7067723/
https://ncbi.nlm.nih.gov/pubmed/32077057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-020-00296-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk